OBJECTIVE: We sought to characterize a novel cohort of patients with lung disease, anti-cyclic citrullinated peptide (CCP) antibody positivity, without rheumatoid arthritis (RA) or other connective tissue disease (CTD). METHODS: The study sample included 74 subjects with respiratory symptoms, evaluated January 2008-January 2010 and found to have a positive anti-CCP antibody but no evidence for RA or other CTD. Each underwent serologic testing, pulmonary physiology testing, and thoracic high-resolution computed tomography (HRCT) scan as part of routine clinical evaluation. RESULTS: The majority of subjects were women, and most were former cigarette smokers. Four distinct radiographic phenotypes were identified: isolated airways disease (54%), isolated interstitial lung disease (ILD) (14%), mixed airways disease and ILD (26%), and combined pulmonary fibrosis with emphysema (7%). This cohort had a predominance of airways disease, either in isolation or along with a usual interstitial pneumonia-pattern of ILD. Among subjects with high-titer anti-CCP positivity (n=33), three developed the articular manifestations of RA during a median follow-up of 449 days. CONCLUSION: We have described a unique cohort of patients with anti-CCP antibody positivity and lung disease in the absence of existing RA or other CTD. The lung phenotypic characteristics of this cohort resemble those of established RA and a few of these patients have developed articular RA within a short period of follow-up. The implications of a positive anti-CCP antibody among patients with lung disease but not RA are not yet known, but we believe requires further investigation.
OBJECTIVE: We sought to characterize a novel cohort of patients with lung disease, anti-cyclic citrullinated peptide (CCP) antibody positivity, without rheumatoid arthritis (RA) or other connective tissue disease (CTD). METHODS: The study sample included 74 subjects with respiratory symptoms, evaluated January 2008-January 2010 and found to have a positive anti-CCP antibody but no evidence for RA or other CTD. Each underwent serologic testing, pulmonary physiology testing, and thoracic high-resolution computed tomography (HRCT) scan as part of routine clinical evaluation. RESULTS: The majority of subjects were women, and most were former cigarette smokers. Four distinct radiographic phenotypes were identified: isolated airways disease (54%), isolated interstitial lung disease (ILD) (14%), mixed airways disease and ILD (26%), and combined pulmonary fibrosis with emphysema (7%). This cohort had a predominance of airways disease, either in isolation or along with a usual interstitial pneumonia-pattern of ILD. Among subjects with high-titer anti-CCP positivity (n=33), three developed the articular manifestations of RA during a median follow-up of 449 days. CONCLUSION: We have described a unique cohort of patients with anti-CCP antibody positivity and lung disease in the absence of existing RA or other CTD. The lung phenotypic characteristics of this cohort resemble those of established RA and a few of these patients have developed articular RA within a short period of follow-up. The implications of a positive anti-CCP antibody among patients with lung disease but not RA are not yet known, but we believe requires further investigation.
Authors: D Makrygiannakis; M Hermansson; A-K Ulfgren; A P Nicholas; A J W Zendman; A Eklund; J Grunewald; C M Skold; L Klareskog; A I Catrina Journal: Ann Rheum Dis Date: 2008-04-15 Impact factor: 19.103
Authors: Alison M Gizinski; Margherita Mascolo; Jennifer L Loucks; Alma Kervitsky; Richard T Meehan; Kevin K Brown; V Michael Holers; Kevin D Deane Journal: Clin Rheumatol Date: 2009-02-28 Impact factor: 2.980
Authors: Ori Elkayam; Refael Segal; Daniele Bendayan; Robert van Uitert; Carla Onnekink; Ger Jm Pruijn Journal: Arthritis Res Ther Date: 2010-01-25 Impact factor: 5.156
Authors: M Kristen Demoruelle; Kylie K Harrall; Linh Ho; Monica M Purmalek; Nickie L Seto; Heather M Rothfuss; Michael H Weisman; Joshua J Solomon; Aryeh Fischer; Yuko Okamoto; Lindsay B Kelmenson; Mark C Parish; Marie Feser; Chelsie Fleischer; Courtney Anderson; Michael Mahler; Jill M Norris; Mariana J Kaplan; Brian D Cherrington; V Michael Holers; Kevin D Deane Journal: Arthritis Rheumatol Date: 2017-05-02 Impact factor: 10.995
Authors: Lindsay B Kelmenson; Brandie D Wagner; Bryan K McNair; Ashley Frazer-Abel; M Kristen Demoruelle; Dylan T Bergstedt; Marie L Feser; Laura K Moss; Mark C Parish; Elizabeth A Mewshaw; Ted R Mikuls; Jess D Edison; V Michael Holers; Kevin D Deane Journal: Arthritis Rheumatol Date: 2019-12-26 Impact factor: 10.995
Authors: H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks Journal: Expert Rev Clin Immunol Date: 2020-01-06 Impact factor: 4.473
Authors: José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante Journal: Clin Rheumatol Date: 2015-08-09 Impact factor: 2.980